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Abstract 19 
 20 
Background: Disease progression in cancer is often associated with loss of weight and lean 21 
tissue and the development of a systemic inflammatory response (SIR) and these have 22 
prognostic value.  The present study investigated the relationship between these factors in 23 
patients with operable colorectal cancer. 24 
 25 
Methods: The study included 322 patients with primary operable colorectal cancer.  In 26 
addition to BMI, pre-operative CT scans were used to define the presence of visceral obesity, 27 
sarcopenia and myosteatosis.  Tumour and patient characteristics were recorded.  Survival 28 
was analysed using univariate and multivariate Cox regression. 29 
 30 
Results: There was no significant association between TNM stage and any measure of body 31 
composition.  The modified Glasgow Prognostic Score (mGPS), was associated with greater 32 
BMI (p=0.021), sarcopenia (p<0.001), and myosteatosis (p=0.004).  On univariate analysis, 33 
there was a significant association between age (p=0.002), ASA grade (p=0.010), TNM stage 34 
(p<0.001), mGPS (p=0.001) and myosteatosis (p=0.017) and disease specific survival.  On 35 
multivariate analysis, age (HR 1.89, 95% CI 1.27-2.79, p=0.002), TNM stage (HR 2.27, 95% 36 
CI 1.45-3.55, p<0.001) and mGPS (HR 1.48, 95% CI 1.08-2.03, p=0.016) remained  37 
prognostic. 38 
 39 
Conclusions: The SIR is a key hallmark of progressive nutritional and functional decline 40 
leading to poorer survival in patients with cancer. 41 
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Introduction 45 
Colorectal cancer is one of the commonest cause of cancer death in the UK and worldwide.  46 
As with most common solid tumours disease progression is associated with a progressive 47 
nutritional and functional decline resulting in poor response to treatment and poor survival  48 
[1-2].  49 
In the past weight loss has been used as an indicator of such nutritional decline and 50 
poor prognosis.  However, in recent years such simple weight loss has become less useful 51 
since many patients in the developed world, at diagnosis, will be overweight/ obese.  It has 52 
now become apparent that even in obese cancer patients there will be significant loss of lean 53 
tissue and this will have prognostic value [3-4].  The ability to use routine CT scans to 54 
measure body composition has resulted in an explosion of interest in the ability of skeletal 55 
muscle mass to predict outcomes in patients with cancer. For example, the disproportionate 56 
loss of lean tissue has been associated with chemotherapy toxicity [5-8], increased risk of 57 
post-operative complications [9-10], poorer outcome and poorer survival [3, 11-12].  58 
Recently, based on such CT analyses, the terms visceral obesity, sarcopenia/myopenia, and 59 
myosteatosis have been defined [3, 11, 13-14].   60 
With specific reference to primary operable colorectal cancer Malietzis and coworkers 61 
in a series of recent publications have reported that a low skeletal muscle index was 62 
associated with poorer cancer specific and overall survival [14].  Moreover, a lower skeletal 63 
muscle index was associated with the presence of a systemic inflammatory response, as 64 
evidenced by an elevated neutrophil lymphocyte ratio (NLR), that, in turn, they have reported 65 
to have prognostic value [15-16].   66 
It has been previously been proposed that the systemic inflammatory response,, given 67 
its association with loss of lean tissue [17], and its established prognostic value [18], would 68 
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form a simple and objective method of identifying patients with different cachexia states  [19-69 
20]. Indeed, systemic inflammation, as evidence by C-reactive protein (CRP) or the modified 70 
Glasgow Prognostic Score (mGPS) is associated with a lower skeletal muscle index in cancer 71 
patients [21-22], poorer functional status [23], and survival [18]. Recently, it has been 72 
reported that the combination of TNM stage and the mGPS stratifies survival following 73 
surgery for colorectal cancer effectively [24].   74 
Therefore, the aim of the present observational study was to examine the relationship 75 
between tumour stage, systemic inflammation, CT measures of body composition and 76 
survival in patients with primary operable colorectal cancer. 77 
78 
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Patients and Methods 79 
 80 
Patients: 81 
Consecutive patients who underwent elective, potentially curative resection for colorectal 82 
cancer between March 2008 and May 2013 at a single centre were identified from a 83 
prospectively maintained database.  Those patients with a preoperative CT scan and a 84 
recorded height and weight were included.  Patients who had undergone emergency surgery, 85 
palliative surgery, or with metastatic disease were not considered for inclusion.   86 
Patients were classified according to Body Mass Index (BMI) as underweight (BMI 87 
<18.5), normal weight (BMI 18.5–24.9), overweight (BMI 25.0–29.9) or obese (BMI >30).  88 
ASA grading was recorded. All tumours were staged according to TNM 5th edition. 89 
Preoperative haematological and biochemical markers were recorded.   90 
The cause and date of death were confirmed with the Registrar General (Scotland) 91 
until 1st May 2016 which served as the censor date.  Informed consent was obtained from 92 
patients prior to surgery.  Ethical approval was granted by the West of Scotland Research 93 
Ethics Committee, Glasgow.   94 
 95 
Methods: 96 
CT images were obtained at the level of the third lumbar vertebra as previously described 97 
[21]. Each image was analysed using a free-ware program (NIH Image J version 1.47, 98 
http://rsbweb.nih.gov/ij/) shown to provide reliable measurements [21].  99 
Region of interest (ROI) measurements were made of visceral fat (VFA), 100 
subcutaneous fat (SFA) (Figure 1), and skeletal muscle areas (SMA) (cm2) (Figure 2) using 101 
standard Hounsfield Unit (HU) ranges (adipose tissue -190 to -30, and skeletal muscle -29 to 102 
+150). These were then normalised for height2 to create indices; total fat index (TFI, cm2/m2), 103 
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subcutaneous fat index (SFI, cm2/m2), visceral fat index (VFI, cm2/m2), and skeletal muscle 104 
index (SMI, cm2/m2).  Skeletal muscle radiodensity (SMD, HU) was measured from the same 105 
ROI used to calculate SMI, as its mean HU.  Visceral obesity was defined as VFA >160cm2 106 
for male patients and >80cm2 for female patients [13].  Sarcopenia was defined as described 107 
by Prado and colleagues [6]; SMI for male patients of <52.4cm2/m2 and <38.5cm2/m2 for 108 
female patients, and also by Martin and colleagues [3]; SMI of <43cm2/m2 if BMI <25kg/m2 109 
and SMI <53cm2/m2 if BMI >25kg/m2 in male patients and SMI <41cm2/m2 in female 110 
patients.  Myosteatosis was defined by SMD <41HU in patients with BMI <25kg/m2 and 111 
<33HU in patients with BMI >25kg/m2 [3]. 112 
Measurements were made by one individual (DB) blind to clinicopathological and 113 
demographic data.  Another individual (SM) performed an independent measurement of 40 114 
patient images to assess inter-rater reliability using intra-class correlation coefficients (ICCC) 115 
(TFA ICCC= 0.999, SFA ICCC=0.997, VFA ICCC=0.996, SMA ICCC=0.995, SMD 116 
ICCC=0.996). 117 
An autoanalyzer was used to measure serum CRP (mg/L) and albumin (g/L) 118 
concentrations (Architect; Abbot Diagnostics, Maidenhead, UK).  The mGPS was derived as 119 
previously described [18]. The neutrophil lymphocyte ratio (NLR) was calculated for each 120 
patient for whom preoperative neutrophil and lymphocyte counts were available, values >3 121 
were considered raised [16].   122 
 123 
Statistical analysis: 124 
The inter-relationship between measures of the systemic inflammatory response and CT 125 
derived measures of body composition was examined using Spearman’s correlation 126 
coefficients.  Correlation was considered to be weak with coefficient values <0.500, and 127 
strong with values >0.800.  Body composition indices were presented as median and range, 128 
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and compared using Mann-Whitney or Kruskal-Wallis tests.  Categorical variables were 129 
analysed using χ2 test for linear-by-linear association, or χ2 test for 2 by 2 tables.   130 
Mortalities within 30 days of the index procedure or during the index  admission were 131 
excluded from subsequent survival analysis.  The time between the date of surgery and the 132 
date of cancer specific death was used to define disease specific survival (DSS).  The time 133 
between the date of surgery and the date of death of any cause was used to define overall 134 
survival (OS).  Survival data were analysed using univariate and multivariate Cox regression.  135 
Those variables associated to a degree of p<0.1 were entered into a backward conditional 136 
multivariate model.  Those body composition variables found to be significantly associated 137 
with survival were entered into a multivariate model with other significant 138 
clinicopathological variables.  139 
Missing data were excluded from analysis on a variable by variable basis.  Two tailed 140 
p values <0.05 were considered statistically significant.  Statistical analysis was performed 141 
using SPSS software (Version 21.0. SPSS Inc., Chicago, IL, USA). 142 
 143 
 144 
 145 
 146 
 147 
 148 
 149 
 150 
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Results 151 
Patients (Table 1): 152 
377 patients were eligible for inclusion over the study period however 55 were excluded due 153 
to either missing anthropometric data or unavailable preoperative CT images resulting in 322 154 
patients for analysis.  Patients were likely to be over 65 years old (67%), overweight or obese 155 
(62%), with some comorbid disease (88%) and node negative disease (64%).    There were 4 156 
postoperative deaths (1%).  297 patients were alive at the censor date with a median follow 157 
up time of 56 months (range 35-96).  Death by any cause occurred in 76 patients (24%); 47 158 
(15%) of which were cancer specific.   159 
 160 
Correlation between preoperative measures of systemic inflammation and CT derived 161 
measures of body composition (Table 2): 162 
There was a positive correlation (rs=0.538) between BMI and visceral obesity, and a positive 163 
correlation  (rs=0.627) between sarcopenia as defined by Prado and colleagues [6] and 164 
sarcopenia as defined by Martin and colleagues [3].  All remaining correlations were weak. 165 
 166 
BMI defined obesity (Table 3): 167 
There was no significant association between BMI defined obesity and TNM stage.  There 168 
was a significant inverse association between BMI defined obesity and mGPS (P<0.05).  In 169 
those patients with an mGPS of 2 a lower proportion of patients were classified as obese by 170 
BMI (>30 kg/m2) compared to those who had an mGPS=0 (13% vs. 31%, p=0.021).  This 171 
remained the case in patients with node negative disease (14% vs. 33%, p=0.029).  172 
 173 
 174 
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CT defined visceral obesity (Table 3): 175 
There was no significant association between CT defined visceral obesity and either TNM 176 
stage or mGPS. 177 
 178 
CT defined sarcopenia (Table 3): 179 
There was no significant association between CT defined sarcopenia and TNM stage.  There 180 
was a significant inverse association between sarcopenia and mGPS (P<0.001).  In those 181 
patients with an mGPS of 2 a higher proportion of patients were classified as sarcopenic [6] 182 
compared to those who had an mGPS=0 (76% vs. 43%, p<0.001).  183 
This remained the case in patients with node negative disease (74% vs. 44%, p=0.001) and 184 
node positive disease (80% vs. 42%, p=0.021).  In those patients with an mGPS of 2 a higher 185 
proportion of patients were classified as sarcopenic [3] compared to those who had an 186 
mGPS=0 (77% vs. 40%, p<0.001). This remained the case in patients with node negative 187 
disease (77% vs. 40%, p=0.001) and node positive disease (100% vs. 41%, p=0.001).   188 
 189 
CT defined myosteatosis (Table 3): 190 
There was no significant association between CT defined myosteatosis and TNM stage. 191 
There was a significant inverse association between myosteatosis and mGPS (P<0.01).  In 192 
those patients with an mGPS of 2 a higher proportion of patients were classified as having 193 
myosteatosis compared to those who had an mGPS=0 (78% vs. 54%, p=0.004).  This 194 
remained the case in patients with node negative disease (80% vs. 56%, p=0.013).  195 
 196 
Body composition and survival (Table 4): 197 
On univariate and multivariate analysis there was a significant association between only 198 
myosteatosis (HR 2.11, 95% CI 1.14-3.92, p=0.017) and cancer specific survival.   199 
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On univariate analysis, there was a significant association between BMI (p=0.004), 200 
myosteatosis (p<0.001) and overall survival.  On multivariate analysis of BMI and 201 
myosteatosis, BMI (HR 0.69, 95% CI 0.54-0.89, p=0.004) and myosteatosis (HR 2.29, 95% 202 
CI 1.38-3.81, p=0.001) remained associated with overall survival. 203 
 204 
Patient characteristics, body composition and survival (Table 4): 205 
On univariate survival analysis, there was a significant association between age (p=0.002), 206 
ASA grade (p=0.010), TNM stage (p<0.001), mGPS (p=0.001), NLR (p=0.050) and 207 
myosteatosis (p=0.017) and disease specific survival.  On multivariate analysis, age (HR 208 
1.89, 95% CI 1.27-2.79, p=0.002), TNM stage (HR 2.27, 95% CI 1.45-3.55, p<0.001) and 209 
mGPS (HR 1.48, 95% CI 1.08-2.03, p=0.016) remained associated with disease specific 210 
survival.  211 
On univariate survival analysis (Table 4) there was a significant association between age 212 
(p<0.001), ASA grade (p<0.001), TNM stage (p=0.001), mGPS (p<0.001), NLR (p=0.019), 213 
BMI (p=0.004), myosteatosis (p<0.001) and overall survival.  On multivariate survival 214 
analysis, age (HR 1.76, 95% CI 1.27-2.44, p=0.001), ASA (HR 1.48, 95% CI 1.06-2.05, 215 
p=0.020), mGPS (HR 1.34, 95% CI 1.04-1.73, p=0.025), TNM stage (HR 1.59, 95% CI 1.14-216 
2.23, p=0.007), and BMI (HR 0.72, 95% CI 0.55-0.93, p=0.013) remained associated with 217 
overall survival.  218 
219 
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Discussion 220 
 221 
In the present study the majority of patients with colorectal cancer were overweight or obese.  222 
In contrast, approximately half were sarcopenic and had myosteatosis.  Although there was 223 
no significant association between BMI, sarcopenia or myosteatosis and TNM stage, a higher 224 
mGPS was associated with lower BMI and with greater sarcopenia and myosteatosis.  225 
Although myosteatosis was consistently associated with poorer survival its prognostic value 226 
was not independent of the mGPS.  The present results are consistent with the concept that 227 
systemic inflammation is a key hallmark of progressive nutritional and functional decline 228 
leading to poorer survival in patients with cancer. 229 
The results of the present study are in keeping with the recent work of Malietzis and 230 
colleagues who, also using CT derived body composition measures, reported that sarcopenia 231 
and myosteatosis were associated with the NLR [15] and that sarcopenia had prognostic 232 
value on survival analysis [14].  In contrast to the present study, sarcopenia was, independent 233 
of NLR, associated with overall and cancer specific survival.  The reasons for the differences 234 
in the prognostic value of sarcopenia and myosteatosis between the above studies are not 235 
clear.  However, in the present study when the prognostic value of mGPS and NLR was 236 
compared directly, the mGPS had superior prognostic value and therefore a more reliable 237 
indicator of the nature of the impact of the systemic inflammatory response on muscle tissue 238 
and survival. 239 
The above results point to a consistent association between the quantity and quality of 240 
the loss of lean tissue and the presence of a systemic inflammatory response.  This is also 241 
confirmed by previous longitudinal studies [25], including historical work [26], and the 242 
recent work of Wallengren and colleagues who reported that, patients with advanced cancer 243 
and a CRP>10mg/l had less muscle mass on study entry and lost muscle mass at an 244 
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accelerated rate during cancer progression [27].  Whether this is a causal association remains 245 
to be determined by intervention studies.  If the loss of lean tissue resulted in the elaboration 246 
of a systemic inflammatory then it might be expected that anabolic agents may be useful in 247 
increasing lean tissue and prolonging survival.  If the elaboration of a systemic inflammatory 248 
response resulted in the loss of lean tissue then it might be expected that anti-inflammatory 249 
agents may be useful in increasing lean tissue and prolonging survival. Further work is 250 
required to explore both of these approaches.  Irrespective, the present results further 251 
substantiate the proposal that there should be a move towards using measures of the 252 
underlying mechanism, i.e. the systemic inflammatory response, to define the cachectic state 253 
[19].   254 
Limitations of the present study include its retrospective nature and that only patients 255 
with an available CT scan were included.  Also, that other methods of body composition were 256 
not included.  In addition, although it might be expected that there would be significant inter-257 
relationships between the different CT derived measured of body composition, there was in 258 
fact limited correlation.  Given the variables taken forward into multivariate analysis, this is 259 
unlikely to have confounded the results of the present study.  Furthermore, the cut off values 260 
applied to the CT body composition parameters used within the present study were derived in 261 
North American patients.  However, despite the possible differences between the colorectal 262 
cancer population in North America and the UK, it is important to note that the findings 263 
reported in the present study with regard to systemic inflammation are similar to those 264 
reported in another study of UK patients which utilised sex specific tertiles rather than cut-off 265 
values [21].  The present study, however, details for the first time the relationships between 266 
TNM stage, the systemic inflammatory response, body composition and survival in patients 267 
with primary operable colorectal cancer.     268 
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In summary, the present results would suggest that the tumour per se was not directly 269 
responsible for the loss of lean tissue and are consistent with the concept that systemic 270 
inflammation is a key hallmark of progressive nutritional and functional decline leading to 271 
poorer survival in patients with cancer. 272 
  273 
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Tables and footnotes 
Table 1: Clinicopathological characteristics, systemic inflammation, body composition and 
outcomes following elective surgery for colorectal cancer 
Characteristic  n=322 (%) 
Clinicopathological   
   
Age <65 106 (33) 
65-74 127 (39) 
>74 89 (28) 
Sex male 174 (54) 
 female 148 (46) 
ASA Score 1 38 (12) 
 2 151 (47) 
 3 123 (38) 
 4 9 (3) 
TNM stage 0 7 (2) 
1 69 (22) 
2 130 (40) 
3 116 (36) 
T stage 0 7 (2) 
 1 35 (11) 
 2 49 (15) 
 3 177 (55) 
 4 54 (17) 
N stage 0 206 (64) 
 1 88 (27) 
 2 28 (9) 
   
Systemic inflammation   
   
mGPS  0 247 (77) 
 1 30 (9) 
 2 45 (14) 
   
NLR ≤3 181 (56)   
 >3 140 (44)   
Body composition   
   
BMI (kg/m2) Underweight (<20) 14 (4) 
 Normal (20-25) 110 (34) 
 Overweight (25-30) 108 (34) 
 Obese (>30) 89 (28) 
Visceral obesity* No 93 (29) 
 Yes 229 (71) 
Sarcopenia (Prado)£ No 164 (51) 
 Yes 158 (49) 
Sarcopenia (Martin)Δ No 170 (53) 
 Yes 152 (47) 
Myosteatosis¥ No 135 (42) 
 Yes 186 (58) 
   
Outcomes   
   
Disease specific survival 5yr % (SE) 86 (2) 
Overall survival 5yr % (SE) 78 (2) 
Abbreviations: BMI body mass index, ASA American Society of Anaesthesiology, NLR neutrophil lymphocyte ratio,  mGPS modified 
Glasgow Prognostic Score,  HU Hounsfield units, VFA visceral fat area, SMI skeletal muscle index, SMD skeletal muscle density,  SE 
standard error, * Visceral obesity; VFA = males >160cm2, females >80cm2  £ Sarcopenia (Prado); SMI = Males <52.4cm2/m2, Females 
<38.5cm2/m2,   Δ Sarcopenia (Martin); SMI Males BMI <25kg/m2 and SMI <43cm2/m2 or BMI >25kg/m2 and SMI <53cm2/m2, Females 
<41cm2/m2,  ¥ Myosteatosis; BMI <25kg/m2 and SMD <41HU, or BMI >25kg/m2 and SMD <33HU        
20 
 
Table 2: Correlation between measures of preoperative systemic inflammation and CT 
derived body composition in patients undergoing elective surgery for colorectal cancer 
Correlation 
coefficient 
(Spearman’s rho) 
mGPS NLR BMI VO Sarcopenia 
(Prado) 
Sarcopenia 
(Martin) 
Myosteatosis 
mGPS - 0.037 -0.160 -0.100 0.218 0.274 0.180 
NLR - - -0.151 -0.091 0.130 -0.011 0.119 
BMI - - - 0.538 -0.418 -0.252 -0.132 
VO - - - - -0.156 -0.029 0.002 
Sarcopenia 
(Prado) 
- - - - - 0.627 0.283 
Sarcopenia 
(Martin) 
- - - - - - 0.176 
Myosteatosis - - - - - - - 
Abbreviations: BMI body mass index, NLR neutrophil lymphocyte ratio,  mGPS modified Glasgow Prognostic Score, VO visceral obesity, 
HU Hounsfield units, TFI total fat index, SFI subcutaneous fat index, VFA visceral fat area, SMI skeletal muscle index, SMD skeletal muscle 
density,  * Visceral obesity; VFA = males >160cm2, females >80cm2  £ Sarcopenia (Prado); SMI = Males <52.4cm2/m2, Females 
<38.5cm2/m2,   Δ Sarcopenia (Martin); SMI Males BMI <25kg/m2 and SMI <43cm2/m2 or BMI >25kg/m2 and SMI <53cm2/m2, Females 
<41cm2/m2,  ¥ Myosteatosis; BMI <25kg/m2 and SMD <41HU, or BMI >25kg/m2 and SMD <33HU        
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Table 3: The relationship between tumour stage, mGPS and measures of body composition in 
patients undergoing elective surgery for colorectal cancer 
TNM 
stage 
 mGPS=0  mGPS=1  mGPS=2  All (mGPS 0-2) P 
 
n BMI obese n(%)  n BMI obese n(%)  n BMI obese n(%)  n 
BMI obese 
n(%) 
 
0-II  152 50 (33)  19 9 (30)  35 5 (14)  206 60 (29) 0.029 
III  95 27 (29)  11 5 (26)  10 1 (10)  116 32 (28) 0.372 
All  247 77 (31)  30 4 (36)  45 6 (13)  322 92 (29) 0.021 
P   0.488   0.293   0.843   0.898  
  n VO* n(%)  n VO* n(%)  n VO* n(%)  n VO* n(%) P 
0-II  152 106 (70)  19 13 (68)  35 18 (51)  206 137 (67) 0.153 
III  95 73 (77)  11 10 (91)  10 9 (90)  116 92 (79) 0.050 
All  247 179 (73)  30 23 (77)  45 27 (60)  322 229 (71) 0.199 
P   0.477   0.340   0.055   0.015  
  
n 
Sarcopenia£ 
(Prado) n(%)  n 
Sarcopenia£ 
(Prado) n(%)  n 
Sarcopenia£ 
(Prado) n(%)  n 
Sarcopenia£ 
(Prado) n(%) P 
0-II  152 67 (44)  19 11 (58)  35 26 (74)  206 104 (51) 0.001 
III  95 40 (42)  11 6 (55)  10 8 (80)  116 54 (47) 0.021 
All  247 107 (43)  30 17 (57)  45 34 (76)  322 158 (49) <0.001 
P   0.894   0.951   0.760   0.562  
  n 
SarcopeniaΔ 
(Martin) n(%)  n 
SarcopeniaΔ 
(Martin) n(%)  n 
SarcopeniaΔ 
(Martin) n(%)  n 
SarcopeniaΔ 
(Martin) n(%) P 
0-II  152 60 (40)  19 10 (53)  35 27 (77)  206 97 (47) <0.001 
III  95 39 (41)  11 6 (55)  10 10 (100)  116 55 (47) 0.001 
All  247 99 (40)  30 16 (53)  45 37 (82)  322 152 (47) <0.001 
P   0.894   1.000   0.168   1.000  
  
n 
Myosteatosis¥ 
n(%)  n 
Myosteatosis¥ 
n(%)  n 
Myosteatosis¥ 
n(%)  n 
Myosteatosis¥ 
n(%) P 
0-II  152 85 (56)  19 11 (58)  35 28 (80)  206 124 (60) 0.013 
III  95 48 (51)  11 7 (64)  10 7 (70)  116 62 (54) 0.190 
All  247 133 (54)  30 18 (60)  45 35 (78)  322 186 (58) 0.004 
P   0.905   0.743   0.498   0.290  
Abbreviations: BMI body mass index, mGPS modified Glasgow Prognostic Score, VO visceral obesity, HU Hounsfield units, TFI total fat 
index, SFI subcutaneous fat index, VFA visceral fat area, SMI skeletal muscle index, SMD skeletal muscle density,  * Visceral obesity; VFA 
= males >160cm2, females >80cm2  £ Sarcopenia (Prado); SMI = Males <52.4cm2/m2, Females <38.5cm2/m2,   Δ Sarcopenia (Martin); SMI 
Males BMI <25kg/m2 and SMI <43cm2/m2 or BMI >25kg/m2 and SMI <53cm2/m2, Females <41cm2/m2,  ¥ Myosteatosis; BMI <25kg/m2 and 
SMD <41HU, or BMI >25kg/m2 and SMD <33HU        
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Table 4: Impact of body composition on survival following elective surgery for colorectal 
cancer 
Survival Variable Univariate HR 
(95% CI) 
P Multivariate HR 
(95% CI) 
P 
DSS      
 BMI (<20/20-25/25-30/>30 kg/m2) 0.74 (0.55-1.01) 0.056 - - 
 Visceral obesity 0.90 (0.51-1.60) 0.730 - - 
 Sarcopenia (Prado) 0.89 (0.49-1.59) 0.682 - - 
 Sarcopenia (Martin) 0.90 (0.50-1.62) 0.724 - - 
 Myosteatosis 2.11 (1.14-3.92) 0.017 2.11 (1.14-3.92) 0.017 
OS      
 BMI (<20/20-25/25-30/>30 kg/m2) 0.70 (0.55-0.89) 0.004 0.69 (0.54-0.89) 0.004 
 Visceral obesity 0.76 (0.49-1.17) 0.215 - - 
 Sarcopenia (Prado) 1.26 (0.79-2.00) 0.338 - - 
 Sarcopenia (Martin) 1.40 (0.88-2.24) 0.154 - - 
 Myosteatosis 2.47 (1.49-4.10) <0.001 2.29 (1.38-3.81) 0.001 
HR Hazard Ratio, CI Confidence Interval ,  BMI body mass index, DSS disease specific survival, OS overall 
survival, VO visceral obesity, HU Hounsfield units, VFA visceral fat area, SMI skeletal muscle index, SMD 
skeletal muscle density,  Visceral obesity; VFA = males >160cm2, females >80cm2 , Sarcopenia (Prado); SMI = 
Males <52.4cm2/m2, Females <38.5cm2/m2,   Sarcopenia (Martin); SMI Males BMI <25kg/m2 and SMI 
<43cm2/m2 or BMI >25kg/m2 and SMI <53cm2/m2, Females <41cm2/m2,  Myosteatosis; BMI <25kg/m2 and 
SMD <41HU, or BMI >25kg/m2 and SMD <33HU        
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
23 
 
Table 5: Impact of stage, systemic inflammation, and body composition on survival following 
elective surgery for colorectal cancer 
Survival Variable Univariate HR 
(95% CI) 
P Multivariate HR 
(95% CI) 
P 
DSS      
 Age 1.72 (1.22-2.43) 0.002 1.89 (1.27-2.79) 0.002 
 Sex 0.88 (0.53-1.46) 0.622 - - 
 ASA 1.59 (1.12-2.27) 0.010 - 0.355 
 mGPS 1.67 (1.25-2.22) 0.001 1.48 (1.08-2.03) 0.016 
 NLR (≤3/>3) 1.67 (1.00-2.80) 0.050 - 0.523 
 TNM stage 2.27 (1.54-3.34) <0.001 2.27 (1.45-3.55) <0.001 
 BMI (<20/20-25/25-30/>30 kg/m2) 0.74 (0.55-1.01) 0.056 - - 
 Myosteatosis 2.11 (1.14-3.92) 0.017 - 0.293 
OS      
 Age 1.99 (1.50-2.62) <0.001 1.76 (1.27-2.44) 0.001 
 Sex 1.24 (0.82-1.87) 0.309 - - 
 ASA 1.86 (1.40-2.47) <0.001 1.48 (1.06-2.05) 0.020 
 mGPS 1.60 (1.27-2.02) <0.001 1.34 (1.04-1.73) 0.025 
 NLR (≤3/>3) 1.63 (1.08-2.45) 0.019 - 0.534 
 TNM stage 1.62 (1.23-2.14) 0.001 1.59 (1.14-2.23) 0.007 
 BMI (<20/20-25/25-30/>30 kg/m2) 0.70 (0.55-0.89) 0.004 0.72 (0.55-0.93) 0.013 
 Myosteatosis 2.47 (1.49-4.10) <0.001 - 0.250 
HR Hazard Ratio, CI Confidence Interval , ASA American Society of Anaesthesiology, NLR neutrophil 
lymphocyte ratio,  mGPS modified Glasgow Prognostic Score, BMI body mass index, DSS disease specific 
survival, OS overall survival, SMD skeletal muscle density, Myosteatosis; BMI <25kg/m2 and SMD <41HU, or 
BMI >25kg/m2 and SMD <33HU        
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Figures and legends 
 
 
Figure 1: Example of selection of CT body composition fat areas using ImageJ software; (A) 
mid-L3 vertebra axial slice from preoperative portal venous phase CT, (B) threshold selection 
of adipose tissue using automatic selection of pixels of radiodensity ranging -190 to -30 
Hounsfield units (HU), (C) region of interest (ROI) selection for total fat area (TFA, cm2), 
(D) ROI selection for visceral fat area (VFA, cm2). 
 
 
Figure 2: Example of selection of CT body composition skeletal muscle area using ImageJ 
software; (A) mid-L3 vertebra axial slice from preoperative portal venous phase CT, (B) 
threshold selection of skeletal muscle tissue using automatic selection of pixels of 
radiodensity ranging -29 to 150 Hounsfield units (HU), (C) region of interest (ROI) selection 
for skeletal muscle area (SMA, cm2) 
 
